Lotus Pharmaceutical Co Ltd (1795) - Total Liabilities
Based on the latest financial reports, Lotus Pharmaceutical Co Ltd (1795) has total liabilities worth NT$17.43 Billion TWD (≈ $549.06 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 1795 cash flow conversion to assess how effectively this company generates cash.
Lotus Pharmaceutical Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Lotus Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 1795 financial resilience to evaluate the company's liquid asset resilience ratio.
Lotus Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lotus Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ducommun Incorporated
NYSE:DCO
|
USA | $599.52 Million |
|
Thanachart Capital Public Company Limited
BK:TCAP
|
Thailand | ฿69.40 Billion |
|
Atea ASA
OL:ATEA
|
Norway | Nkr16.70 Billion |
|
Americas Silver Corp
TO:USA
|
Canada | CA$184.49 Million |
|
GCM Grosvenor Inc
NASDAQ:GCMG
|
USA | $686.33 Million |
|
Alten SA
PA:ATE
|
France | €1.41 Billion |
|
CoreCivic Inc
NYSE:CXW
|
USA | $1.85 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Lotus Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Lotus Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lotus Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lotus Pharmaceutical Co Ltd (2009–2024)
The table below shows the annual total liabilities of Lotus Pharmaceutical Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$18.92 Billion ≈ $596.11 Million |
+20.84% |
| 2023-12-31 | NT$15.66 Billion ≈ $493.31 Million |
0.00% |
| 2022-12-31 | NT$15.66 Billion ≈ $493.32 Million |
+54.22% |
| 2021-12-31 | NT$10.15 Billion ≈ $319.88 Million |
-7.76% |
| 2020-12-31 | NT$11.01 Billion ≈ $346.81 Million |
+8.20% |
| 2019-12-31 | NT$10.17 Billion ≈ $320.54 Million |
+41.84% |
| 2018-12-31 | NT$7.17 Billion ≈ $225.99 Million |
-9.91% |
| 2017-12-31 | NT$7.96 Billion ≈ $250.85 Million |
+15.68% |
| 2016-12-31 | NT$6.88 Billion ≈ $216.86 Million |
+1.65% |
| 2015-12-31 | NT$6.77 Billion ≈ $213.33 Million |
-9.22% |
| 2014-12-31 | NT$7.46 Billion ≈ $235.00 Million |
+1354.11% |
| 2013-12-31 | NT$512.97 Million ≈ $16.16 Million |
+14.56% |
| 2012-12-31 | NT$447.79 Million ≈ $14.11 Million |
-14.66% |
| 2011-12-31 | NT$524.73 Million ≈ $16.53 Million |
+6.27% |
| 2010-12-31 | NT$493.75 Million ≈ $15.56 Million |
+97.35% |
| 2009-12-31 | NT$250.19 Million ≈ $7.88 Million |
-- |
About Lotus Pharmaceutical Co Ltd
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, central nervous system, cardiovascular diseases, woman health, and anti-obesity. The company also engages in retail of clinical machines;… Read more